Heterocyclic TREM2 Agonists for Neuroimmune Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for neurodegenerative diseases such as Alzheimer's disease focus on targeting pathological hallmarks like amyloid and Tau, but there is a need for activators of the Triggering Receptor Expressed on Myeloid Cells 2 (TREM2) to address the neuroimmune aspects implicated in these diseases.
Innovation Solution
Development of heterocyclic compounds that act as activators of TREM2, potentially formulated into pharmaceutical compositions to stimulate microglial responses and modulate neuroinflammatory processes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If current therapies target pathological hallmarks like amyloid and Tau, then disease progression can be addressed, but the neuroimmune aspects implicated in these diseases remain unaddressed
Solution Approach 1:
The patent segments the therapeutic approach by separating the targeting of pathological hallmarks (amyloid/Tau) from the activation of neuroimmune pathways (TREM2). This allows independent optimization of each mechanism while addressing both aspects of neurodegenerative disease pathology.
Solution Approach 2:
The patent introduces TREM2 as an intermediary receptor that mediates between microglial activation and disease pathology. By activating TREM2, the therapy creates a signaling cascade that indirectly addresses neuroinflammation and enhances microglial function without directly targeting amyloid or Tau.
2Reliability
If TREM2 activators are developed to address neuroimmune aspects, then microglial responses can be enhanced, but new therapeutic classes must be discovered and validated
Solution Approach 1:
The patent employs heterocyclic chemical structures with specific molecular parameters (ring sizes, substituent patterns, heteroatom configurations) to optimize TREM2 binding affinity and activation efficacy. Systematic variation of these parameters allows tuning of therapeutic properties.
Solution Approach 2:
The patent utilizes composite heterocyclic molecular structures combining multiple functional moieties (e.g., pyridine rings, piperidine groups, carbonyl groups) to achieve both high TREM2 affinity and favorable pharmacological properties, effectively creating multi-functional therapeutic molecules.
Data Source
AI summary
The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 (“TREM2”).This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.